Zhengye Biotechnology Holding Limited
$0.95
▼
-3%
2026-04-21 10:27:01
www.jlzybio.com
NCM: ZYBT
Explore Zhengye Biotechnology Holding Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$47.54 M
Current Price
$0.95
52W High / Low
$14.3 / $0.68
Stock P/E
—
Book Value
$0.91
Dividend Yield
0.05%
ROCE
4.81%
ROE
-6.38%
Face Value
—
EPS
$-0.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
277
Beta
—
Debt / Equity
23.49
Current Ratio
1.49
Quick Ratio
0.88
Forward P/E
—
Price / Sales
0.33
Enterprise Value
$154.54 M
EV / EBITDA
-69.83
EV / Revenue
1
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ANI Pharmaceuticals, Inc. | $81.73 | 23.13 | $1.81 B | 0.06% | 6.99% | 16.16% | $99.5 / $56.71 | $25.8 |
| 2. | Harrow, Inc. | $40.5 | — | $1.51 B | — | 10.06% | -8.47% | $54.85 / $21.12 | $1.41 |
| 3. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 4. | Regencell Bioscience Holdings Limited | $29.09 | — | $13.89 B | — | -57.45% | -54.81% | $83.6 / $0.7 | $0.01 |
| 5. | Cardiol Therapeutics Inc. | $1.51 | — | $230.46 M | — | -162.05% | -1.59% | $2.17 / $1.23 | $0.08 |
| 6. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 7. | Amneal Pharmaceuticals, Inc. | $13.26 | 58.7 | $4.23 B | — | 14.23% | -80.04% | $15.42 / $7.01 | $-0.23 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 186.36 M | 211.65 M | 260.27 M | 214.07 M |
| Operating Profit | 17.17 M | 47.64 M | 66.09 M | 55.6 M |
| Net Profit | 11.31 M | 31.46 M | 46.73 M | 38.96 M |
| EPS in Rs | 0.24 | 0.66 | 0.99 | 0.82 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 493.25 M | 499.89 M | 519.67 M | 445.28 M |
| Total Liabilities | 140.71 M | 160.62 M | 162.81 M | 126.44 M |
| Equity | 283.96 M | 272.85 M | 296.5 M | 267.47 M |
| Current Assets | 177.57 M | 189.24 M | 214.31 M | 164.94 M |
| Current Liabilities | 135.91 M | 150.23 M | 152.23 M | 125.63 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | 41.05 M | 48.18 M | 17.34 M | 31.81 M |
| Investing CF | -27.66 M | -11.77 M | -27.33 M | -26.27 M |
| Financing CF | -22.13 M | -18.98 M | 13.46 M | -3.05 M |
| Free CF | 13.27 M | 36.58 M | -9.99 M | 5.41 M |
| Capex | -27.77 M | -11.6 M | -27.33 M | -26.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -11.95% | -18.68% | 21.58% | — |
| Earnings Growth % | -64.04% | -32.69% | 19.96% | — |
| Profit Margin % | 6.07% | 14.86% | 17.96% | 18.2% |
| Operating Margin % | 9.21% | 22.51% | 25.39% | 25.98% |
| Gross Margin % | 48.99% | 55.52% | 56.82% | 58.58% |
| EBITDA Margin % | 22.86% | 34.06% | 32.87% | 32.76% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.